Abstract: A method for treatment of irritation or damage to conical or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, by applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.

Abstract: The present invention provides polymersomes comprising non-biodegradable amphiphilic block-copolymers and their enteral (e.g., oral) or topical use in the treatment of an ammonia or ammonia methylated analog-associated disease or disorder or symptom thereof (e.g., hyperammonemia or trimethylaminuria). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid. It also provides a method of making the polymersome comprising mixing the copolymer-containing organic solvent phase with an aqueous phase containing the acid.

Abstract: Disclosed is a composition including controlled release particles, wherein each of the controlled release particles includes: (a) a core including at least one hydrophobic active ingredient; and (b) a wall at least partially surrounding the core and including: (i) an outer layer including a copolymer of polyacrylamide and polyacrylate; (ii) an intermediate layer under the outer layer and including a polyurea; (iii) an inner layer under the intermediate layer and including an acrylate copolymer; and optionally (iv) an optional outer layer above the outer layer and including a quaternary amine containing moiety, wherein the inner layer is a mesh and the controlled release particles are effective to retain the at least one hydrophobic active ingredient upon exposure to water and effective to release the at least one hydrophobic active ingredient in response to friction. A method for preparing the composition is also disclosed.

Abstract: The present invention relate to liquid cleansing compositions comprising 12-HSA which are both processable and stable. Applicants have defined a specific composition window (defined by specific types and ratios of fatty acid and/or fatty acid soaps, as well as critical ceiling for 12-HSA and floor levels of polyol) where these objectives can be met.

Abstract: The invention relates to the use of an oral bolus for drying-off cattle, preferably daily cattle, as well as methods of improving/facilitating the drying-off of cattle, reducing the milk production in pregnant and/or lactating cattle, decreasing milk accumulation in the udder of cattle, increasing the daily lying time of cattle, inducing a mild and temporary metabolic acidosis in cattle, reducing the dry matter intake (DMI) in cattle and/or reducing urine pH in cattle, preferably dairy cattle, comprising administering to such cattle at least one oral bolus, preferably on the last milking day and/or before dry-off.

Abstract: The present invention belongs to the fields of pharmaceuticals and cosmetics, and concerns on the one hand a medicament for the inhibition of and refers also on the cosmetic, non-therapeutic use for the treatment of hyperpigmentation, particularly induced by sun light radiation, preferably induced by visible light radiation.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, the compounds of Formula I: in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of central nervous system (CNS) diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

Abstract: The present invention relates to liquid pharmaceutical compositions comprising daptomycin, methods of providing such compositions and the use thereof. Provided herein are formulations comprising daptomycin, one or more polar protic solvents, and mixtures thereof. Formulations according to the present invention can further comprise polar aprotic solvent and/or source of calcium.

Abstract: The present invention relates to a fluid/creamy pigmented hydrogen peroxide-based oxidising composition, to be used in combination with persulfates-based hair bleaches or with dyes, lightening, super-lightening products. The composition of the semi-finished product includes hydrogen peroxide in various titles in proportions from 1% to 12% by weight, plus other substances in addition to a first dye which provides the semi-finished product with a yellow/green colour at an acid pH. By combining the oxidising composition (first product) with bleaching products of various nature/lightening dyes (second product) in an emulsion, the pH of the emulsion becomes strongly alkaline, from the initial 2-3 it may increase up to 11.5. In this pH transition from acid to alkaline, the oxidising emulsion changes its colour from yellow/green to blue.

Abstract: The present invention relates to: a composition for transdermal delivery, comprising 1) a nanoemulsion comprising an active ingredient, saturated lecithin, phytosteryl/behenyl/octyldodecyl lauroyl glutamate, a polyol, and water, and 2) a modified layered double hydroxide; and a preparation method therefor.

Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Abstract: Compositions and methods for stimulating erogenous zones of female and male subjects are disclosed. More particularly, the present disclosure relates to compositions for topical application to the female and male genitalia that increase cell membrane excitability and to methods of using the compositions for treating sexual dysfunction and enhancing sexual arousal and facilitating orgasm.

Abstract: The invention provides a personal cleansing composition comprising: (i) an aqueous continuous phase including cleansing surfactant; (ii) one or more oily liquid conditioning agents for skin and/or hair wherein the agent is solubilized in wormlike micelles in the aqueous continuous phase via the incorporation of at least one inorganic electrolyte and at least one linker molecule; (iii) one or more cationic deposition polymers which are selected from cationic polygalactomannans having a mean charge density at pH7 from 0.2 to 2 meq per 10 gram; and (iv) a hair substantive cationic conditioning polymer which is a homopolymer of (3-acrylamidopropyl) trimethyl ammonium chloride.

Abstract: The present disclosure relates to an antiperspirant composition for a roll-on application comprising a) at least one antiperspirant active substance including an inorganic or organic salt of aluminum, zirconium or a mixture thereof, b) a rice starch and c) a hydrophobically modified clay mineral. Furthermore, the present disclosure relates to a roll-on applicator including a composition as contemplated herein, and a non-therapeutic use of a composition as contemplated herein.

Abstract: A powder additive for a keratin fiber coloring or bleaching agent or developer is provided. The powder additive includes a dicarboxylic acid containing from about 2 to about 10 carbon atoms, selected from the group of malic acid, D-tartaric acid, L-tartaric acid, meso-tartaric acid, racemic acid, alpha-ketoglutaric acid, beta-ketoglutaric acid, oxaloacetic acid, maleic acid, fumaric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, azelaic acid, sorbic acid, a salt of these dicarboxylic acids, and mixtures thereof. The powder additive also includes an amino acid or a salt of an amino acid and an alkalisilicate. The powder additive has no greater than about 10% by weight water, based on the weight of the powder additive. In addition, the powder additive includes particles and at least about 80% of the particles have an average particle size of less than 200 ?m.

Abstract: Disclosed is a composition including (per 100% weight): a) 90 wt.-% to 99.0 wt.-% water including, in dissolved form, 0.002 mol/L to 0.1 mol/L of at least one salt of ammonium cation or of a monovalent or multivalent metal cation with an organic or inorganic anion; b) 0.5 wt.-% to 5 wt.-% of a crosslinked anionic polyelectrolyte; and c) 0.5 wt.-% to 5 wt.-% of a compound having formula (II): R1—(O—CH2—CH2)p—OH (II), where the weight ratio of the crosslinked anionic polyelectrolyte to the compound of formula (II) is greater than or equal to 0.2 and less than or equal to 2.0, and the molar ratio of the compound of formula (II) to the salt greater than or equal to 0.05 and less than or equal to 1. Also disclosed is a composition in cosmetics and a method for lightening the thickened salt-rich composition.

Abstract: A visible light-curable chitosan derivative, a hydrogel thereof, and a preparation method therefor are disclosed. The visible light-curable glycol chitosan derivative is curable by light in the visible light range and has a wound healing activity. A hydrogel obtained by cross-linkage of the visible light-curable glycol chitosan derivative using visible light has a wound healing effect per se, and further, a hydrogel obtained by cross-linkage in a combination of one or more growth factors has an excellent wound healing effect. In addition, a glycol chitosan hydrogel that can prevent the denaturation of contained drugs and growth factors due to the cross-linkage by visible light and is optimized for application to a wet dressing dosage form can be prepared.

Abstract: Compositions and methods for effecting skin lightening and/or even toning involving the use of select aryl alkanones.

Abstract: The present disclosure relates to a composition that includes lemongrass, castor oil, cedarwood oil, geraniol, sodium laurel sulfate, and corn oil for repelling and killing mosquitos. In one aspect of the inventive compositions comprise Guatemalan lemongrass, Juniperus virginiana and cedarwood oil. Some compositions further comprise mint oil, e.g., and Montana mint oil. Compositions according to the inventive subject matter kill insects at multiple stages in their life cycle including adult insects, larvae, and disrupt the egg cycle. In another aspect, the inventive compositions repel insects and retain repellency and insecticidal potency over a longer period of time than other natural insect repellents.